OXcan CEO Dr Peter Jianrui Liu with chairman Brad Wilson and COO Andreas Halner (from left to right). Credit: © Oxford Cancer Analytics.

Oxford Cancer Analytics (OXcan) has secured $11m in Series A funding for the development of its liquid biopsy blood tests for early cancer detection.

This investment increases OXcan’s total funding to $16.7m, enabling the company to develop and commercialise the minimally invasive tests globally.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Cross-Border Impact Ventures and We Venture Capital led the funding round, with contributions from existing investors Eka Ventures and Civilization Ventures. The round also saw participation from other investors, including DigitalDx Ventures, Macmillan Cancer Support (Innovation Impact Investment Portfolio), and OKG Capital.

In conjunction with the funding, the senior investment manager at We Venture Capital, Gemma Sturt, as well as Cross-Border Impact Ventures’ managing partner, Annie Theriault, have joined OXcan’s board of directors.

Additionally, OXcan has appointed Dr Heinrich Roder as senior vice president of research and development, bringing more than two decades of experience in lung cancer liquid biopsy and commercialisation.

Dr Roder said: “Having developed blood-based proteomic tests for lung cancer for over two decades, I appreciate the difficulty of detecting cancers early through liquid biopsy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Convinced that OXcan’s unique approach can address this clinical need, I feel privileged to join the team. Together, our plan is to offer this novel technological approach to large markets worldwide to start a new era of early detection and improve patient outcomes.”

Founded in 2020 by CEO Dr Peter Jianrui Liu and chief operating officer Dr Andreas Halner, OXcan’s patented approach and its ‘advanced’ proteomics lab have enabled the development of a machine learning platform.

As the leading cause of cancer deaths worldwide, lung cancer is OXcan’s primary focus.

The company’s protein-based blood test claims to provide a molecular signature for individuals at high risk of this cancer type.